Although daily disposable usage is on the rise in many parts of the world, including the United States, one thing we need to continue to keep in the forefront of our minds is best practices for contact lens care. This includes compliance with scheduled wear periods, in addition to the contact lens care regimen. Contact lens care systems are often thought of in terms of their ability to disinfect lenses, but it is critical to remember that they also clean contact lenses and potentially also help to improve comfort through other advanced additives. As we have always said, it is optimal to prescribe a specific lens care system to your patients to emphasize the importance of the particular care system you intend for them to use in terms of biocompatibility with their contact lens and ocular surface. And, as always, remember to continually instruct your patients about their required wear schedules.
Jason J. Nichols, OD, MPH, PhD
Voluntary Recall of PeroxiClear in the US and Canada
Bausch + Lomb is conducting a voluntary recall, proposed Class II, of PeroxiClear 3% Hydrogen Peroxide Cleaning & Disinfecting Solution in the U.S. and Canada.
Although this voluntary recall represents low risk to the consumer and is unlikely to cause serious health consequences, according to the company, the company chose to initiate this voluntary action out of an abundance of caution and as part of its ongoing commitment to quality and customer satisfaction.
The company chose to initiate this voluntary action based on internal testing that simulated normal product use. Testing showed occasional occurrences where the residual peroxide remaining in the lens case after neutralization was out of product specification.
PeroxiClear solution is unlikely to cause serious health consequences. If the residual hydrogen peroxide is above product specification the user of the product could experience temporary symptoms of burning/stinging, irritation, red eye and in rare circumstances other more serious health consequences.
The voluntary recall is limited to the U.S. and Canada. The PeroxiClear Hydrogen Peroxide Cleaning & Disinfecting Solution is the only product affected in this voluntary recall.
The company has directly contacted U.S. and Canadian retailers, wholesalers, and eyecare professionals who have been shipped this product to initiate the recall and inform them of the steps they should take to return the product.
Voluntary Recalled Product Details
Product: PeroxiClear 3% Hydrogen Peroxide Cleaning & Disinfecting Solution
Lot Numbers: All Lots
The 2017 Global Specialty Lens Symposium will be held January 26-29, 2017 at the Rio Hotel in Las Vegas, Nevada.
The GSLS is a must-attend meeting, brought to you by Contact Lens Spectrum, focusing on the successful management of ocular conditions using today's specialty contact lenses. This meeting will include insightful presentations by international experts in the field, hands-on demonstrations of cutting-edge products and valuable continuing education credits.
Photrexa Viscous and Photrexa Now Available in the U.S.
Avedro, Inc. is now shipping Photrexa Viscous and Photrexa, the drugs used in corneal cross-linking procedures with the KXL System. On April 15, 2016, Avedro received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System used in corneal collagen cross-linking for the treatment of progressive keratoconus. Subsequently on July 15, 2016, the company received U.S. FDA approval for the products’ second indication—for the treatment of corneal ectasia following refractive surgery.
Photrexa Viscous and Photrexa are photoenhancers indicated for use with the KXL System. Corneal collagen cross-linking with Avedro’s Photrexa Viscous, Photrexa and the KXL system is the first and only cross-linking therapy approved by the FDA. For more information, visit www.avedro.com/en-us.
#ChangingLives - X-Cel Specialty Contacts Continue Partnership With Doctors Worldwide to Provide the Gift of Sight
X-Cel Specialty Contacts partners with doctors around the world to provide specialty contact lenses free of charge regardless of a patient’s economic and social status. Since, March 2015, over three thousand patients in over sixty-five countries have benefited from the #ChangingLives campaign.
X-Cel’s #ChangingLives campaign was born as a means to assist the millions of people who are in desperate need of vision correction but have limited economic resources and are unable to get the help they need. If they are able to visit an eyecare professional, they often do not have sufficient means to purchase the contact lenses diagnosed for their condition. Many of the patients involved in the campaign are diagnosed as legally blind with irregular cornea problems, aphakia, and myopia, among others. The outstanding success of the campaign is owed to the practitioners serving the optical industry worldwide who not only donate their time and resources to those who cannot afford vision care, but do so with admirable compassion and generosity.
For more information on the inspirational stories of these doctors and patients around the world, follow the #ChangingLives campaign on X-Cel Specialty Contacts’ Facebook page: www.facebook.com/xcelspecialtycontacts.
Visioneering Technologies, Inc., (VTI), has named Tony Sommer to the position of senior vice president of Sales and Marketing. Sommer will direct planning, development, and execution of growth plans and business strategies for the NaturalVue Brand contact lens portfolio.
Sommer has nearly two decades of multi-disciplinary experience in the packaged goods, health care, and medical device industries. He has served in a variety of U.S. and international executive roles, across a number of business divisions, with leading companies including General Mills, Coca Cola, CIBA Vision/Novartis and Bausch + Lomb. A decorated combat veteran, Sommer saw service in Operation Desert Storm and Operation Iraqi Freedom.
Sommer holds an MBA from Oklahoma City University and has a bachelor’s degree in international affairs from the United States Air Force Academy. He is based at VTI’s headquarters in the Atlanta area.
A corneal GP lens wearer for over 30 years suddenly developed a contact lens impression on the cornea. These images show a cornea with no contact lens on, corneal staining but no serious injury. The patient suffers from hypertyroidism.
We thank Karen Abiantum for this image and welcome photo submissions from our other readers! It is easy to submit a photo for consideration for publishing in Contact Lenses Today. Simply visit http://www.cltoday.com/upload/upload.aspx to upload your image. Please include a detailed explanation of the photo and your full name, degree or title, and city/state/country.
About one third of the United States’ population suffers from myopia.1 Its prevalence is believed to be increasing,2 and correcting myopia is costing the health care system billions of dollars.3 Thus, reducing or preventing myopia will greatly benefit society. There is currently some promising research that indicates that off-label use of center-distance multifocal and orthokeratology contact lenses is able to reduce myopia development by about 50%.4, 5 While the full treatment mechanisms of these contact lenses is unknown, it is hypothesized that they act by reducing peripheral hyperopic blur that is present even after correcting myopia with single vision contact lens correction.6, 7
If contact lenses obtain FDA indication for myopia treatment, eyecare providers will have an additional reason for monitoring contact lens compliance. This concern was recently addressed by a large case study by Turnbull et al. who offered self-selecting patients who attended their myopia control referral clinic orthokeratology, multifocal contact lenses, low dose atropine, and patient education.8 Turnbull et al.’s study found that patients tended to choose orthokeratology (49.1%) and multifocal contact lenses (28.1%) over atropine (2.6%) and no treatment beyond patient education (19.3%).8 They also found that patients treated with orthokeratology and multifocal contact lenses had similar treatment benefits (92% vs. 91% progression rate reduction compared to pretreatment rates) and that orthokeratology and multifocal contact lenses wearers (92.9% vs. 90.1% met study criteria) were similarly compliant with follow-up schedules.8 The authors also noted that the parents of patients anecdotally reported that their children had high treatment compliance.8
While additional research is needed to fully evaluate the long-term treatment effects, effects of compliance on treatment, and optimal contact lenses designs, the community finally has a well-tolerated potential myopia treatment option.8
1. Vitale S, Ellwein L, Cotch MF, Ferris FL, 3rd, Sperduto R. Prevalence of refractive error in the United States, 1999-2004. Arch Ophthalmol 2008;126:1111-1119.
2. Vitale S, Sperduto RD, Ferris FL, 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol 2009;127:1632-1639.
3. Javitt JC, Chiang YP. The socioeconomic aspects of laser refractive surgery. Arch Ophthalmol 1994;112:1526-1530.
4. Cho P, Cheung SW, Edwards M. The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res 2005;30:71-80.
5. Walline JJ, Greiner KL, McVey ME, Jones-Jordan LA. Multifocal contact lens myopia control. Optom Vis Sci 2013;90:1207-1214.
6. Smith EL, 3rd, Ramamirtham R, Qiao-Grider Y, et al. Effects of foveal ablation on emmetropization and form-deprivation myopia. Invest Ophthalmol Vis Sci 2007;48:3914-3922.
7. Berntsen DA, Kramer CE. Peripheral defocus with spherical and multifocal soft contact lenses. Optom Vis Sci 2013;90:1215-1224.
8. Turnbull PR, Munro OJ, Phillips JR. Contact Lens Methods for Clinical Myopia Control. Optom Vis Sci 2016;93:1120-1126.
The research is in and we have concluded that there is something better. I just received in my office a pile of boxes that add up to the size of a new refrigerator. I checked with my contact lens rep and she said that they wanted to switch out my single use toric fitting set. I have been doing pretty well with this lens and didn’t really notice an issue. When asked about why they made the change, they said that they thought they could make the fitting set a little better and improve the practice efficiency. Really? That’s quite the move to make my practice more successful. Sure enough, this major contact lens company has realized that the return on their investment is worth it. They are electing to replace all the single use toric fitting sets out there and ditch all the old ones because the system could be better. WOW. I have to commend our industry partners for always looking for better. Always looking for ways to make the practices more successful. THANK YOU.
Corneal Hydration Control in Fuchs' Endothelial Corneal Dystrophy.
The purpose of this study was to assess corneal hydration control across a range of severity of Fuchs' endothelial corneal dystrophy (FECD) by measuring the percent recovery per hour (PRPH) of central corneal thickness after swelling the cornea and to determine its association with corneal morphologic parameters.
Twenty-three corneas of 23 phakic FECD patients and 8 corneas of 8 healthy control participants devoid of guttae were graded (modified Krachmer scale). Effective endothelial cell density (ECDe) was determined from the area of guttae and local cell density in confocal microscopy images. Steady-state corneal thickness (CTss) and standardized central corneal backscatter were derived from Scheimpflug images. Corneal swelling was induced by wearing a low-oxygen transmissible contact lens for 2 hours in the morning. De-swelling was measured over 5 hours after lens removal or until corneal thickness returned to CTss. Percent recovery per hour was 100 × (1 - e-k), where k was determined from CT(t) = (de-kt) + CTss, and where d was the initial change from CTss.
After contact lens wear, corneas swelled by 9% (95% CI 9-10). Percent recovery per hour was 49%/h (95% CI 41-57) in controls and 37%/h in advanced FECD (95% CI 29-43, P = 0.028). Low PRPH was associated with disease severity, low ECDe, and increased anterior and posterior corneal backscatter. Anterior backscatter was associated with PRPH in a multivariable model (R2 = 0.44).
The researchers concluded that corneal hydration control is impaired in advanced FECD and is inversely related to anterior corneal backscatter. Anterior corneal backscatter might serve as an indicator of impaired endothelium in FECD.
Wacker K, McLaren JW, Kane KM, Baratz KH, Patel SV. Corneal Hydration Control in Fuchs' Endothelial Corneal Dystrophy. Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):5060-5065. doi: 10.1167/iovs.16-20205.